Prognosis of heart failure patients with reduced and preserved ejection fraction and coexistent chronic obstructive pulmonary disease
|
|
- Amberlynn Neal
- 5 years ago
- Views:
Transcription
1 European Journal of Heart Failure (2010) 12, doi: /eurjhf/hfq157 Prognosis of heart failure patients with reduced and preserved ejection fraction and coexistent chronic obstructive pulmonary disease Beom-June Kwon, Dong-Bin Kim*, Sung-Won Jang, Ki-Dong Yoo, Keun-Woong Moon, Byung Ju Shim, Seo-Hee Ahn, Eun-Ju Cho, Tae-Ho Rho, and Jae-Hyung Kim Division of Cardiology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul , Republic of Korea Received 1 February 2010; revised 24 April 2010; accepted 4 June 2010; online publish-ahead-of-print 22 September 2010 Aims The long-term prognosis of patients with heart failure with preserved left ventricular ejection fraction (HFPEF) and coexistent chronic obstructive pulmonary disease (COPD) has not been previously investigated. The primary aim of this study was to determine whether the long-term prognosis of HFPEF patients with COPD differs from that of heart failure patients with reduced left ventricular ejection fraction (HFREF) and COPD. The secondary aim was to identify independent predictors of event-free survival in patients with HF and COPD.... Methods We investigated 184 patients with coexistent HF and COPD. Heart failure with preserved left ventricular ejection and results fraction was present in 98 cases (53%) and HFREF in the remaining 86 cases (47%). Mean follow-up time was days. Cardiovascular/pulmonary hospitalization or mortality occurred in 71 patients (39%). No significant difference was observed between the two study groups in terms of event-free survival (P ¼ 0.457), but event-free survival was found to be independently associated with New York Heart Association (NYHA) class [III vs. I, hazard ratio (HR) 2.92, 95% confidence interval (CI) ], Global initiative for chronic Obstructive Lung Disease (GOLD) stage (III vs. I, HR 3.20, 95% CI ), systemic hypertension (SHT; HR 2.99, 95% CI ), and pulmonary hypertension (PH; HR 4.35, 95% CI ).... Conclusion In HF patients with coexisting COPD, cardiovascular and pulmonary event-free survival of HFPEF was found to be similar to that of HFREF over 3 years follow-up. Furthermore, severe NYHA class, severe GOLD stage, SHT, and PH were found to be independent predictors of event-free survival Keywords Heart failure COPD Left ventricular systolic function Prognosis Introduction Co-morbidities play an important role in heart failure (HF). 1 Heart failure and chronic obstructive pulmonary disease (COPD) are commonly encountered in clinical practise. The prevalence of COPD is 20 40% among patients with HF, and the prevalence of HF is 20 30% among patients with COPD. 2 6 Among the co-morbid conditions commonly associated with HF, COPD frequently delays the diagnosis of HF, and vice versa. Either HF or COPD is a predictor of prognosis in patients with each condition Limited data are available on the natural course of coexistent HF and COPD, and most of the studies performed have focused on HF with reduced left ventricular ejection fraction (HFREF). 2,5 The prevalence of diastolic heart failure (DHF) or HF with preserved left ventricular ejection fraction (HFPEF) is as 1,11 13 high as 30 55% among those with HF and they have similar re-admission rates, but lower mortality than HFREF. 11,14,15 The long-term prognosis of PEF patients with combined HF and COPD is not known. In this study, we aimed to evaluate the long-term prognosis of HFPEF with COPD when compared with that of HFREF with COPD, and also to identify common prognostic factors in patients with coexistent HF and COPD. * Corresponding author. Tel: , Fax: , dbkimmd@empas.com Published on behalf of the European Society of Cardiology. All rights reserved. & The Author For permissions please journals.permissions@oxfordjournals.org.
2 1340 B.-J. Kwon et al. Methods Study population We conducted a retrospective cohort study of 494 patients with coexistent HF and COPD. Patients were followed in the outpatient clinic of St. Paul s Hospital, Seoul, Korea, between 1 February 2002 and 30 December Exclusion criteria were: New York Heart Association (NYHA) functional class IV, Consecutive Global initiative for chronic Obstructive Lung Disease (GOLD) stage IV, age,30 years, chronic pulmonary thromboembolism, cor pulmonale, right ventricular HF, primary pulmonary hypertension (PH), or any serious co-morbid disease. Overall, 184 patients with coexistent HF and COPD were included. Heart failure was diagnosed according to the ALLHAT criteria based on 1 sign (rales, ankle oedema 2+, tachycardia 120 b.p.m., cardiomegaly by chest X-ray, chest X-ray characteristics of HF, S 3 gallop, or jugular venous distension) and 1 concurrent symptom (paroxysmal nocturnal dyspnoea, orthopnoea, or dyspnoea at rest or on ordinary exertion). 16 The diagnosis of COPD was made using spirometric pulmonary function testing. The following measures of lung function were used: forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), and FEV1/FVC ratio. COPD patients were divided into three GOLD stages (I, II, and III). GOLD stage I (mild COPD) was defined as post-bronchodilator FEV1/FEV ratio of,70% and post-bronchodilator FEV1.80% of predicted. GOLD stage II (moderate COPD) was defined as post-bronchodilator FEV1/FEV ratio of,70% and post-bronchodilator FEV % of predicted, and GOLD stage III (severe COPD) was defined as postbronchodilator FEV1/FEV ratio of,70% and post-bronchodilator FEV % of predicted. 17 Patients were dichotomized by left ventricular systolic function into HFPEF and HFREF groups, based on left ventricular ejection fractions (LVEF) of 50% or of,50% as determined by transthoracic echocardiography (TTE). 5 Echocardiograms were performed in the stable stages of HF and COPD treatment, and LVEF was calculated from the conventional apical two- and fourchamber images, using the modified Simpson s method. Demographic data, co-morbidities, laboratory results, and medications were abstracted from medical records. The outcome events examined were cardiovascular/pulmonary hospitalization or mortality. Clinical follow-up was censored at 3 years (1095 days). We defined a current smoker as a person who had smoked any cigarettes in the last month. Systemic hypertension (SHT) was defined as a systolic blood pressure 140 mmhg or a diastolic blood pressure 90 mmhg, 18 chronic renal disease (CKD) as an estimated glomerular filtration rate by Modification of Diet in Renal Disease (MDRD) formula,60 ml/min/1.73m 2, anaemia as a haemoglobin,13.0 g/dl in men or,12.0 g/dl in women based on WHO criteria. Pulmonary hypertension was defined as a pulmonary artery systolic pressure.35 mmhg at rest in the absence of pulmonary outflow obstruction by TTE, 19,20 hypercholesterolaemia as a total cholesterol 5.7 mmol/l, weight loss as a percentage reduction in body mass of.5% vs. baseline within 1 year, and left ventricular hypertrophy as a left ventricular mass index [LVMI; left ventricular mass (g)/body surface area (m 2 )]. 125 g/m 2 in men or 110 g/m 2 in women. 21 Body mass index (BMI) was defined as body weight in kilograms divided by the square of the patient s height in metres and was categorized as,18.5, , or.25 kg/m Statistical analysis We summarized baseline characteristics in the HFPEF and HFREF groups using means and standard deviations for continuous variables, and numbers and percentages for categorical variables. The independent samples t-test and the x 2 test were used to analyse continuous and categorical variables, respectively. Observed cardiovascular or pulmonary hospitalization or mortality was summarized using Kaplan Meier survival curves and the independence of relationships was determined using a Cox proportional hazards regression model. Univariate variables with a P-value of,0.20 were entered into the multivariate logistic models. Statistical significance was accepted for P-values of,0.05. Results Baseline characteristics of the heart failure with preserved left ventricular ejection fraction and heart failure with reduced left ventricular ejection fraction groups with coexisting COPD Of the 184 patients with coexistent HF and chronic obstructive pulmonary disease, HFPEF was present in 98 cases (53%) and HFREF in the remaining 86 (47%). Mean follow-up time was days, and a maximum follow-up of 3 years was achieved for 63 (34%) patients. Baseline clinical and medication characteristics of patients are shown in the Tables 1 and 2. Prognosis of heart failure with preserved left ventricular ejection fraction compared with heart failure with reduced left ventricular ejection fraction in patients with coexisting COPD Cardiovascular/pulmonary hospitalization or mortality occurred in 71 patients (38.6%) during the follow-up period: 33 (38%) in the HFPEF group and 39 (39%) in the HFREF group. No significant difference was found between the HFPEF and HFREF groups in terms of event-free survival over 3 years of follow-up (P ¼ 0.457; Figure 1). Furthermore, there was also no significant difference between the two groups at 1 year of follow-up (P ¼ 0.117, data not shown). In addition, there was no difference in the incidence of cardiovascular or pulmonary events between the two groups (Table 3). Of 71 events, 64 were due to hospitalizations (23 to acute decompensated HF, 3 to ischaemic heart disease, 3 to arrhythmia, 2 to stroke, and 33 to pulmonary events) and the remaining 7 were due to deaths (2 to HF, 1 to ischaemic heart disease, 1 to arrhythmia, and 3 to pulmonary events). Univariate analysis for predictors of cardiovascular or pulmonary event-free survival in patients with coexistent heart failure and COPD Cardiovascular or pulmonary event-free survival was associated with NYHA class (P ¼ 0.003), GOLD stage (P ¼ 0.002), and BMI (P ¼ 0.042; Table 4). Other variables were not found to be significantly associated.
3 Long-term prognosis in HF/chronic obstructive pulmonary disease 1341 Table 1 Baseline characteristics of patients with heart failure with preserved left ventricular ejection fraction and heart failure with reduced left ventricular ejection fraction Variables HFPEF (n 5 98) HFREF (n 5 86) All HF (n 5 184)... Age (years) Male [n (%)] 38 (39) 54 (63) 92 (50) Current smoker [n (%)] 30 (31) 26 (29) BMI (kg/m 2 ) NYHA class [n (%)] I 15 (15) 19 (22) 34 (19) II 61 (62) 37 (43) 98 (53) III 22 (23) 30 (35) 52 (28) Ejection fraction (%) Ischaemic aetiology of HF 16 (16) 35 (41) 51 (28) GOLD stage [n (%)] I 47 (47) 24 (28) 71 (39) II 25 (26) 38 (44) 63 (34) III 26 (27) 24 (28) 50 (27) Co-morbid conditions Diabetes [n (%)] 29 (30) 29 (34) 58 (32) Hypertension [n (%)] 43 (44) 47 (55) 90 (49) CKD [n (%)] 33 (34) 36 (42) 69 (38) Anaemia [n (%)] 48 (49) 49 (57) 97 (53) PH [n (%)] 20 (22) 20 (23) 40 (22) Atrial fibrillation 43 (44) 26 (30) 69 (38) Biochemical markers BNP (pg/ml) Hs-CRP (mg/dl) TC (mmol/l) Weight loss [n (%)] 27 (28) 27 (31) 54 (29) LVMI (g/m 2 ) Values are expressed as means + SD, unless otherwise stated. HFPEF, heart failure with preserved left ventricular ejection fraction; HFREF, heart failure with reduced left ventricular ejection fraction; n, number of patients; GOLD, Global initiative for chronic Obstructive Lung Disease; CKD, chronic renal disease; PH, pulmonary hypertension; TC, total cholesterol; BMI, body mass index; Hs-CRP, high sensitive C-reactive protein; LVMI, Left ventricular mass index. Multivariate Cox proportional hazards regression model analysis for cardiovascular or pulmonary event-free survival in patients with coexistent heart failure and COPD Age, NYHA class, GOLD stage, SHT, PH, high sensitive C-reactive protein, and BMI, which were all P, 0.20 by univariate analysis, were subjected to Cox proportional hazards regression analysis (Table 5). Cardiovascular or pulmonary event-free survival was found to be independently associated with NYHA class [III vs. I, hazard ratio (HR) 2.92, 95% confidence interval (CI) ], GOLD stage (III vs. I, HR 3.20, 95% CI ), SHT (HR 2.99, 95% CI ), and PH (HR 4.35, 95% CI ). Discussion The present study demonstrates for the first time that the long-term prognosis of patients with coexistent HF and chronic obstructive pulmonary disease are similar regardless of left ventricular systolic function, and that NYHA class, GOLD stage, SHT, and PH were predictors of prognosis. Most importantly, we directly compared the long-term prognosis between HFPEF and HFREF in patients with coexistent chronic obstructive pulmonary disease. Our study differs from previous studies in many ways. 2 4,23 First, we included patients with both HFPEF and HFREF. Second, we observed cardiovascular/pulmonary hospitalizations or mortality over a relatively long follow-up of 3 years. Third, we included a relatively large number of subjects when compared with previous studies. 5
4 1342 B.-J. Kwon et al. Table 2 Medication at baseline in patients with coexistent heart failure and chronic obstructive pulmonary disease, according to the presence of heart failure with preserved left ventricular ejection fraction or heart failure with reduced left ventricular ejection fraction Variables HFPEF HFREF All HF (n 5 98) (n 5 86) (n 5 184) Cardiovascular drugs Beta-blocker [n (%)] 15 (15) 24 (28) 39 (22) ACEI and ARB [n (%)] 52 (53) 51 (59) 103 (56) CCB [n (%)] 22 (22) 10 (12) 32 (17) Diuretics [n (%)] 81 (83) 76 (88) 157 (85) Spironolactone [n (%)] 56 (57) 57 (67) 113 (61) Digoxin [n (%)] 50 (52) 61 (72) 111 (60) Pulmonary drugs Theophylline [n (%)] 75 (77) 66 (77) 141 (77) Beta-2 agonist [n (%)] 40 (41) 37 (43) 77 (42) Steroid [n (%)] 31 (32) 33 (38) 64 (35) Values are expressed as means + standard deviation, unless otherwise stated. HF, heart failure; COPD, chronic obstructive pulmonary disease; HFPEF, heart failure with preserved left ventricular ejection fraction; HFREF, heart failure with reduced left ventricular ejection fraction; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker. Figure 1 Survival curves for each group according to left ventricular systolic function. There was no difference in event-free survival between the two groups with coexistent heart failure and chronic obstructive pulmonary disease. Our results show that the prognosis of HFPEF is similar to that of HFREF irrespective of accompanying chronic obstructive pulmonary disease. Despite markedly different degrees of left Table 3 Cause of hospitalization or mortality in patients with heart failure with preserved left ventricular ejection fraction and heart failure with reduced left ventricular ejection fraction Variable HFPEF HFREF P-value (n 5 33) (n 5 38) Cardiovascular events [n (%)] 19 (58) 16 (42) Acute decompensated HF (n) Ischaemic heart disease (n) 2 2 Arrhythmia (n) 3 1 Stroke (n) 1 1 Pulmonary events [n (%)] (Acute exacerbation of COPD or Pneumonia) 14 (42) 22 (58) HFPEF, heart failure with preserved left ventricular ejection fraction; HFREF, heart failure with reduced left ventricular ejection fraction; n, number of patients; HF, heart failure; COPD, chronic obstructive pulmonary disease. ventricular systolic function, remodelling, and structure, HFPEF has pathophysiological abnormalities that are qualitatively similar to those of HFREF, including severely reduced exercise performance, neuroendocrine activation, and reduced quality of life. 24 Furthermore, similar rates of cardiac arrest, acute coronary syndrome, renal failure, and admission to the intensive care unit or coronary care unit 11 and common predictors of death 25 have been reported in the two groups. Despite similar rates of complications, patients with a HFPEP are less likely to receive primary care from a cardiologist and are less likely to have had a cardiology consultation than patients with a HFREF. 7 In addition, although there have been considerable advances in the treatment of HFREF, relatively little progress has been made in the management of HFPEF. 26 Heart failure with preserved left ventricular ejection fraction and DHF are not the same entities. A diagnosis of DHF is particularly difficult to establish in patients with chronic obstructive pulmonary disease. In the present study, we measured only LVEF and therefore could not confirm the necessary parameters for diagnosis of true DHF by TTE. 27 Accordingly, it is not certain whether our results on HFPEF can be extrapolated to true DHF combined with chronic obstructive pulmonary disease. The prevalences of HFPEF and HFREF in patients with coexistent chronic obstructive pulmonary disease were 53 and 47% in the present study. In another study, the reported prevalences of HFPEF (LVEF 45%) with chronic obstructive pulmonary disease and HFREF (LVEF, 45%) with chronic obstructive pulmonary disease were 49 and 51%, respectively. 2 NYHA class, GOLD stage, SHT, and PH were found to be independent predictors of event-free survival in patients with coexistent HF and chronic obstructive pulmonary disease. NYHA class and GOLD stage have previously been identified as significant predictors of survival in HF 28 and chronic obstructive pulmonary disease, 17 respectively, and according to our results these relationships are preserved even in cases of coexistent HF and chronic obstructive pulmonary disease. In a previous study, GOLD stage also showed a trend towards a higher risk of adverse events in
5 Long-term prognosis in HF/chronic obstructive pulmonary disease 1343 Table 4 Univariate analysis for prediction of cardiovascular or pulmonary event-free survival in patients with coexistent heart failure and chronic obstructive pulmonary disease Variables HR (95% CI) P-value Age 1.46 ( ) Male 0.93 ( ) NYHA class NYHA I NYHA II 0.87 ( ) NYHA III 2.58 ( ) Ischaemic origin of HF 1.44 ( ) GOLD stage GOLD I GOLD II 0.93 ( ) GOLD III 2.27 ( ) Ejection fraction (%) 1.00 ( ) Current smoker 0.99 ( ) Diabetes 1.17 ( ) Hypertension 1.58 ( ) CKD 1.28 ( ) Hypercholesterolaemia 0.78 ( ) Anaemia 1.02 ( ) Pulmonary hypertension 1.44 ( ) Atrial fibrillation 0.96 ( ) BNP (pg/ml) I(,100) II ( 100 and,500) 1.07 ( ) III ( 500) 1.12 ( ) Hs-CRP 2.23 ( ) BMI (kg/m 2 ) I(,18.5) II ( 18.5 and,25) 0.52 ( ) III ( 25) 0.40 ( ) Weight loss 1.00 ( ) LVH 0.67 ( ) HF, congestive heart failure; COPD, chronic obstructive pulmonary disease; GOLD, Global initiative for chronic Obstructive Lung Disease; CKD, chronic kidney disease; Hs-CRP, high sensitive C-reactive protein; BMI, body mass index; LVH, left ventricular hypertrophy; HR, hazard ratio; CI, confidence interval. patients with coexistent HF and chronic obstructive pulmonary disease, which reached significance at GOLD stages III and IV in HF. 2 Chronic obstructive pulmonary disease has been shown to increase the risk of cardiovascular disease two- to three-fold. 29 Systemic hypertension is a common and important cause of HF, 30 and our study shows that SHT is also an important predictor of survival in cases of coexistent HF and chronic obstructive pulmonary disease. Pulmonary hypertension is known to be a predictor of prognosis in HF 31 and chronic obstructive pulmonary disease, 32 and was also found to be an independent predictor of event-free survival in patients with coexistent HF and chronic obstructive pulmonary disease in our study. Table 5 Multivariate Cox proportional hazards regression model analysis for cardiovascular or pulmonary event-free survival in patients with coexistent heart failure and chronic obstructive pulmonary disease Variables HR (95% CI) P NYHA class NYHA I NYHA II 0.67 ( ) NYHA III 2.92 ( ) GOLD stage GOLD I GOLD II 1.09 ( ) GOLD III 3.20 ( ) System hypertension 2.98 ( ) Pulmonary hypertension 4.35 ( ),0.001 HF, heart failure; COPD, chronic obstructive pulmonary disease; NYHA, New York Heart Association; GOLD, Global initiative for chronic Obstructive Lung Disease; HR, hazard ratio; CI, confidence interval. Our study has several limitations. First, it is limited by its retrospective nature. Second, although we included a relatively large population when compared with previous studies, the sample size was still relatively small. Third, some overlap between HFPEP and HFREF groups may exist in terms of pathophysiology and outcomes, because of the relatively high mean LVEF of % in the HFREF group. Because of the limited sample size, our findings concerning the prognostic predictors should be confirmed in larger studies. In conclusion, these findings indicate that in patients with coexistent HF and chronic obstructive pulmonary disease, the cardiovascular or pulmonary event-free survival of HFPEF and HFREF are similar over a follow-up of 3 years. Severe NYHA class, severe GOLD stage, SHT, and PH were found to be independent prognostic predictors of event-free survival in patients with coexistent HF and chronic obstructive pulmonary disease. Acknowledgements The statistical analyses performed in this article were advised by Catholic Medical Center Clinical Research Coordinating Center. Conflict of interest: none declared. References 1. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10: Mascarenhas J, Lourenco P, Lopes R, Azevedo A, Bettencourt P. Chronic obstructive pulmonary disease in heart failure. Prevalence, therapeutic and prognostic implications. Am Heart J 2008;155:
6 1344 B.-J. Kwon et al. 3. Iversen KK, Kjaergaard J, Akkan D, Kober L, Torp-Pedersen C, Hassager C, Vestbo J, Kjoller E. Chronic obstructive pulmonary disease in patients admitted with heart failure. J Intern Med 2008;264: Le Jemtel TH, Padeletti M, Jelic S. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol 2007;49: Rutten FH, Cramer MJ, Lammers JW, Grobbee DE, Hoes AW. Heart failure and chronic obstructive pulmonary disease: an ignored combination? Eur J Heart Fail 2006;8: Hawkins NM, Jhund PS, Simpson CR, Petrie MC, Macdonald MR, Dunn FG, Macintyre K, McMurray JJ. Primary care burden and treatment of patients with heart failure and chronic obstructive pulmonary disease in Scotland. Eur J Heart Fail 12: Wu AW, Herbert R, Niefeld M, Weller W, Gerstenblith G, Anderson GF, Braunstein JB. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol 2003;42: Hawkins NM, Huang Z, Pieper KS, Solomon SD, Kober L, Velazquez EJ, Swedberg K, Pfeffer MA, McMurray JJ, Maggioni AP. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Eur J Heart Fail 2009;11: Boudestein LC, Rutten FH, Cramer MJ, Lammers JW, Hoes AW. The impact of concurrent heart failure on prognosis in patients with chronic obstructive pulmonary disease. Eur J Heart Fail 2009;11: Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003;107: Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, Gong Y, Liu PP. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006;355: Aurigemma GP, Gottdiener JS, Shemanski L, Gardin J, Kitzman D. Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: the cardiovascular health study. J Am Coll Cardiol 2001;37: Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol 1999; 33: Chatterjee K, Massie B. Systolic and diastolic heart failure: differences and similarities. J Card Fail 2007;13: Philbin EF, Rocco TA Jr, Lindenmuth NW, Ulrich K, Jenkins PL. Systolic versus diastolic heart failure in community practice: clinical features, outcomes, and the use of angiotensin-converting enzyme inhibitors. Am J Med 2000;109: Einhorn PT, Davis BR, Massie BM, Cushman WC, Piller LB, Simpson LM, Levy D, Nwachuku CE, Black HR. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis. Am Heart J 2007;153: Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001;163: Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. J Am Med Assoc 2003;289: Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G, Vahanian A, Auricchio A, Bax J, Ceconi C, Dean V, Filippatos G, Funck-Brentano C, Hobbs R, Kearney P, McDonagh T, McGregor K, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Vardas P, Widimsky P, Al Attar N, Andreotti F, Aschermann M, Asteggiano R, Benza R, Berger R, Bonnet D, Delcroix M, Howard L, Kitsiou AN, Lang I, Maggioni A, Nielsen-Kudsk JE, Park M, Perrone-Filardi P, Price S, Domenech MT, Vonk-Noordegraaf A, Zamorano JL. Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30: Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, Gaine S. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:40S 47S. 21. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Manolis A, Nilsson PM, Redon J, Struijker-Boudier HA, Viigimaa M, Adamopoulos S, Bertomeu V, Clement D, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, O Brien E, Ponikowski P, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B, The task force for the management of arterial hypertension of the European Society of H, The task force for the management of arterial hypertension of the European Society of C Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28: Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, Eckel RH. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006;113: Hernandez AF, Hammill BG, O Connor CM, Schulman KA, Curtis LH, Fonarow GC. Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J Am Coll Cardiol 2009;53: Kitzman DW, Little WC, Brubaker PH, Anderson RT, Hundley WG, Marburger CT, Brosnihan B, Morgan TM, Stewart KP. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. J Am Med Assoc 2002;288: Lenzen MJ, Scholte op Reimer WJ, Boersma E, Vantrimpont PJ, Follath F, Swedberg K, Cleland J, Komajda M. Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. Eur Heart J 2004;25: Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008;359: Hatle L. How to diagnose diastolic heart failure a consensus statement. Eur Heart J 2007;28: Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, Anand I, Maggioni A, Burton P, Sullivan MD, Pitt B, Poole-Wilson PA, Mann DL, Packer M. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 2006;113: Curkendall SM, DeLuise C, Jones JK, Lanes S, Stang MR, Goehring E Jr, She D. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 2006;16: Stokes J 3rd, Kannel WB, Wolf PA, D Agostino RB, Cupples LA. Blood pressure as a risk factor for cardiovascular disease. The Framingham Study 30 years of follow-up. Hypertension 1989;13:I13 I Ghio S, Gavazzi A, Campana C, Inserra C, Klersy C, Sebastiani R, Arbustini E, Recusani F, Tavazzi L. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol 2001;37: Chaouat A, Bugnet AS, Kadaoui N, Schott R, Enache I, Ducolone A, Ehrhart M, Kessler R, Weitzenblum E. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172:
Heart Failure and COPD: Common Partners, Common Problems. Nat Hawkins Liverpool Heart and Chest Hospital
Heart Failure and COPD: Common Partners, Common Problems Nat Hawkins Liverpool Heart and Chest Hospital Disclosures: No conflicts of interest Common partners, common problems COPD in HF common partners
More informationHFpEF, Mito or Realidad?
HFpEF, Mito or Realidad? Ileana L. Piña, MD, MPH Professor of Medicine and Epidemiology/Population Health Associate Chief for Academic Affairs -- Cardiology Montefiore-Einstein Medical Center Bronx, NY
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationOnline Appendix (JACC )
Beta blockers in Heart Failure Collaborative Group Online Appendix (JACC013117-0413) Heart rate, heart rhythm and prognostic effect of beta-blockers in heart failure: individual-patient data meta-analysis
More informationNCAP NATIONAL CARDIAC AUDIT PROGR AMME NATIONAL HEART FAILURE AUDIT 2016/17 SUMMARY REPORT
NCAP NATIONAL CARDIAC AUDIT PROGR AMME NATIONAL HEART FAILURE AUDIT 2016/17 SUMMARY REPORT CONTENTS PATIENTS ADMITTED WITH HEART FAILURE...4 Demographics... 4 Trends in Symptoms... 4 Causes and Comorbidities
More informationTherapeutic Targets and Interventions
Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium
More informationDiagnosis is it really Heart Failure?
ESC Congress Munich - 25-29 August 2012 Heart Failure with Preserved Ejection Fraction From Bench to Bedside Diagnosis is it really Heart Failure? Prof. Burkert Pieske Department of Cardiology Med.University
More informationn Kristensen, S. L., Jhund, P. S., Køber, L., McKelvie, R. S., Zile, M. R., Anand, I. S., Komajda, M., Cleland, J. G.F., Carson, P. E., and McMurray, J. J.V. (2015) Relative importance of history of heart
More informationPrevention of Atrial Fibrillation and Heart Failure in the Hypertensive Patient
Prevention of Atrial Fibrillation and Heart Failure in the Hypertensive Patient The Issue of Primary Prevention of A.Fib. (and Heart Failure) and not the Prevention of Recurrent A.Fib. after Electroconversion
More informationDetection of Atrial Fibrillation Using a Modified Microlife Blood Pressure Monitor
nature publishing group Detection of Atrial Fibrillation Using a Modified Microlife Blood Pressure Monitor Joseph Wiesel 1, Lorenzo Fitzig 1, Yehuda Herschman 2 and Frank C. Messineo 1 Background Hypertension
More informationGender Differences in Comorbidities of Heart Failure Patients with Preserved or Reduced Left Ventricular Ejection Fraction
Article ID: WMC005439 ISSN 2046-1690 Gender Differences in Comorbidities of Heart Failure Patients with Preserved or Reduced Left Ventricular Ejection Fraction Peer review status: No Corresponding Author:
More informationThe role of angiotensin II receptor blockers in the management of heart failure
European Heart Journal Supplements (2005) 7 (Supplement J), J10 J14 doi:10.1093/eurheartj/sui057 The role of angiotensin II receptor blockers in the management of heart failure John J.V. McMurray* Department
More informationDeclaration of conflict of interest
Declaration of conflict of interest Prevalence and main features of resistant hypertension in Central and Eastern Europe: data from the G. Brambilla 1, G. Seravalle 2, R. Cifkova 3, C. Farsang 4, S. Laurent
More informationIdentification of patients with heart failure and PREserved systolic Function : an Epidemiologic Regional study
Identification of patients with heart failure and PREserved systolic Function : an Epidemiologic Regional study Dr. Antonio Magaña M.D. (on behalf I-PREFER investigators group) Stockholm, Sweden, August
More informationKnowledge and Implementation of the New European Guide in the Management of Arterial Hypertension. The Cigema Survey
Pharmaceuticals 2009, 2, 11-32; doi:10.3390/ph2020011 Article OPEN ACCESS Pharmaceuticals ISSN 1424-8247 www.mdpi.com/journal/pharmaceuticals Knowledge and Implementation of the New European Guide in the
More informationHeart Failure with Preserved EF (HFPEF) Epidemiology and management
Heart Failure with Preserved EF (HFPEF) Epidemiology and management Karl Swedberg Senior Professor of Medicine Sahlgrenska Academy University of Gothenburg Gothenburg, Sweden e-mail: karl.swedberg@gu.se
More informationUniversity of Massachusetts Medical School Kimberly A. Fisher University of Massachusetts Medical School Worcester
University of Massachusetts Medical School escholarship@umms GSBS Dissertations and Theses Graduate School of Biomedical Sciences 7-30-2014 Impact of COPD on the Mortality and Treatment of Patients Hospitalized
More informationALLHAT. U.S. Department of Health and Human Services. National Institutes of Health. National Heart, Lung, and Blood Institute
U.S. Department of Health and Human Services National Institutes of Health National Heart, Lung, and Blood Institute Review of Heart Failure Events in the Antihypertensive and Lipid Lowering Treatment
More informationNational Horizon Scanning Centre. Irbesartan (Aprovel) for prevention of cardiovascular complications in patients with persistent atrial fibrillation
Irbesartan (Aprovel) for prevention of cardiovascular complications in patients with persistent atrial fibrillation August 2008 This technology summary is based on information available at the time of
More informationIn 2003, the Seventh Report of the Joint
H Y P E R T E N S I O N A N D D I A B E T E S D E B A T E S Treatment of Prehypertension in Diabetes and Metabolic Syndrome What are the pros? JULIAN SEGURA, MD LUIS M. RUILOPE, MD In 2003, the Seventh
More informationHeFSSA Practitioners Program 2017 Theme The Patient Journey: Feel Good and Live Long. Case Study 2
HeFSSA Practitioners Program 2017 Theme The Patient Journey: Feel Good and Live Long Case Study 2 HEART FAILURE WITH MID-RANGE EJECTION FRACTION TREATMENT OPTIONS CLINICAL CASE MEDICAL HISTORY 59-year-old
More informationHeart Failure Management. Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist
Heart Failure Management Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist Heart failure prevalence is expected to continue to increase¹ 21 MILLION ADULTS WORLDWIDE
More informationComorbidities in HF COPD Chronic Obstructive Pulmonary Disease Gerasimos Filippatos Athens, Greece
Comorbidities in HF COPD Chronic Obstructive Pulmonary Disease Gerasimos Filippatos Athens, Greece Epidemiology of heart failure in chronic obstructive pulmonary disease (COPD) patients and vice versa.
More informationAnalytical Methods: the Kidney Early Evaluation Program (KEEP) The Kidney Early Evaluation program (KEEP) is a free, community based health
Analytical Methods: the Kidney Early Evaluation Program (KEEP) 2000 2006 Database Design and Study Participants The Kidney Early Evaluation program (KEEP) is a free, community based health screening program
More informationHeart Failure Guidelines For your Daily Practice
Heart Failure Guidelines For your Daily Practice Juan M. Aranda, Jr., MD, FACC, FHFSA Professor of Medicine Director of Heart Failure and Cardiac Transplantation University of Florida College of Medicine
More informationIncidence and Predictors of Stent Thrombosis after Percutaneous Coronary Intervention in Acute Myocardial Infarction
Incidence and Predictors of Stent Thrombosis after Percutaneous Coronary Intervention in Acute Myocardial Infarction Sungmin Lim, Yoon Seok Koh, Hee Yeol Kim, Ik Jun Choi, Eun Ho Choo, Jin Jin Kim, Mineok
More informationHeart Failure in Women: Dr Goh Ping Ping Cardiologist Asian Heart & Vascular Centre
Heart Failure in Women: More than EF? Dr Goh Ping Ping Cardiologist Asian Heart & Vascular Centre Overview Review pathophysiology as it relates to diagnosis and management Rational approach to workup:
More informationHeart Failure A Disease for the Internist?
Heart Failure A Disease for the Internist? Dr Chris Davidson Sussex Cardiac Centre BRIGHTON UK Hot Topics in Heart Failure Drug treatments Valsartan / neprilysin inhib Investigations BNP and others Devices
More informationHeart failure and co-morbidities
Heart failure and co-morbidities Stefano Taddei Department of Clinical and Experimental Medicine University of Pisa, Italy Declared receipt of grants and contracts from Novartis, Servier, Boehringer Declared
More informationCOPD as a comorbidity of heart failure in elderly patients
COPD as a comorbidity of heart failure in elderly patients Professor Mitja Lainscak, MD, PhD, FESC, FHFA Departments of Cardiology and Research&Education, General Hospital Celje Faculty of Medicine, University
More informationManagement of Stage B Heart Failure
KSC 2017 Management of Stage B Heart Failure Byung Su Yoo, MD., PhD. Division of Cardiology, Wonju College of Medicine, Yonsei University, South Korea Focused on Symptom ASLVSD, ASLVDD LVH HF progression
More informationDiastolic Heart Failure. Edwin Tulloch-Reid MBBS FACC Consultant Cardiologist Heart Institute of the Caribbean December 2012
Diastolic Heart Failure Edwin Tulloch-Reid MBBS FACC Consultant Cardiologist Heart Institute of the Caribbean December 2012 Disclosures Have spoken for Merck, Sharpe and Dohme Sat on a physician advisory
More informationHEART failure with preserved left ventricular systolic
Journal of Gerontology: MEDICAL SCIENCES 2005, Vol. 60A, No. 10, 1339 1344 Copyright 2005 by The Gerontological Society of America Association of Diastolic Dysfunction and Outcomes in Ambulatory Older
More informationPrevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes
Cardiovasc Drugs Ther (2017) 31:545 549 DOI 10.1007/s10557-017-6754-x ORIGINAL ARTICLE Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes
More informationMode of Death in Patients With Heart Failure and Reduced vs. Preserved Ejection Fraction
Circulation Journal Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp ORIGINAL ARTICLE Heart Failure Mode of Death in Patients With Heart Failure and Reduced vs. Preserved Ejection
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Is there a mortality risk associated with aspirin use in heart failure? Results from a large community based cohort Margaret Bermingham, Mary-Kate Shanahan, Saki Miwa,
More informationCongestive Heart Failure or Heart Failure
Congestive Heart Failure or Heart Failure Dr Hitesh Patel Ascot Cardiology Group Heart Failure Workshop April, 2014 Question One What is the difference between congestive heart failure and heart failure?
More informationBeta Blockers Should Not be Used as First Line Antihypertensive Agent
Debate Beta Blockers Should Not be Used as First Line Antihypertensive Agent M. K. Sharma, MD, DNB, S. C. Manchanda MD, DM, New Delhi, India Introduction Hypertension is an important public health problem
More informationARIC Manuscript Proposal # PC Reviewed: 2/10/09 Status: A Priority: 2 SC Reviewed: Status: Priority:
ARIC Manuscript Proposal # 1475 PC Reviewed: 2/10/09 Status: A Priority: 2 SC Reviewed: Status: Priority: 1.a. Full Title: Hypertension, left ventricular hypertrophy, and risk of incident hospitalized
More informationNormal systolic blood pressure and risk of heart failureinusmalephysicians
European Journal of Heart Failure (2009) 11, 1129 1134 doi:10.1093/eurjhf/hfp141 Normal systolic blood pressure and risk of heart failureinusmalephysicians Kathryn A. Britton 1,2 *, J. Michael Gaziano
More informationManagement of COPD and CHF: drugs that should be preferred or avoided
Management of COPD and CHF: drugs that should be preferred or avoided Dr John T. Parissis, Heart Failure Unit, Attikon University Hospital, Athens, Greece Disclosures: Research grants by Abbott USA and
More informationDisclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17
Disclosures Advances in Chronic Heart Failure Management I have nothing to disclose Van N Selby, MD UCSF Advanced Heart Failure Program May 22, 2017 Goal statement To review recently-approved therapies
More informationDisclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017
Advances in Chronic Heart Failure Management Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017 I have nothing to disclose Disclosures 1 Goal statement To review recently-approved therapies
More informationManagement of heart failure with preserved ejection fraction
Management of heart failure with preserved ejection fraction Webb J, Jackson T, Claridge S, Sammut E, Behar J, Carr-White G. Management of heart failure with preserved ejection fraction. Practitioner 2015;259
More informationSleep Disordered Breathing and HH with Preserved Ejection Fraction:
Sleep Disordered Breathing and HH with Preserved Ejection Fraction: Pr Thibaud DAMY Heart Failure Unit Department of Cardiology CHU Mondor, Créteil, France Definition of HF-PEF The diagnosis of HF-PEF
More informationEchocardiography analysis in renal transplant recipients
Original Research Article Echocardiography analysis in renal transplant recipients S.A.K. Noor Mohamed 1*, Edwin Fernando 2, 1 Assistant Professor, 2 Professor Department of Nephrology, Govt. Stanley Medical
More informationAtrial Fibrillation and Heart Failure: A Cause or a Consequence
Atrial Fibrillation and Heart Failure: A Cause or a Consequence Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania November
More informationOutcome of Heart Failure with Preserved Ejection Fraction in a Population-Based Study
The new england journal of medicine original article Outcome of Heart Failure with Preserved Ejection Fraction in a Population-Based Study R. Sacha Bhatia, M.D., M.B.A., Jack V. Tu, M.D., Ph.D., Douglas
More informationHEART FAILURE IN WOMEN. Marian Limacher, MD Division of Cardiovascular Medicine University of Florida
HEART FAILURE IN WOMEN Marian Limacher, MD Division of Cardiovascular Medicine University of Florida Outline Epidemiology Clinical Overview Why HF is such a challenge State of the Field Heart Failure Adjudication
More informationEvaluation of a diagnostic pathway in heart failure in primary care, using electrocardiography and brain natriuretic peptide guided echocardiography
Evaluation of a diagnostic pathway in heart failure in primary care, using electrocardiography and brain natriuretic peptide guided echocardiography Rebecka Karlsson Pardeep Jhund 1 Material and methods
More informationRisk Factors for Ischemic Stroke: Electrocardiographic Findings
Original Articles 232 Risk Factors for Ischemic Stroke: Electrocardiographic Findings Elley H.H. Chiu 1,2, Teng-Yeow Tan 1,3, Ku-Chou Chang 1,3, and Chia-Wei Liou 1,3 Abstract- Background: Standard 12-lead
More informationHEART FAILURE: PHARMACOTHERAPY UPDATE
HEART FAILURE: PHARMACOTHERAPY UPDATE 3 HEART FAILURE REVIEW 1 5.1 million x1.25 = 6.375 million 40 years old = MICHAEL F. AKERS, PHARM.D. CLINICAL PHARMACIST CENTRACARE HEALTH, ST. CLOUD HOSPITAL HF Diagnosis
More informationSleep Apnea and Heart Failure
Sleep Apnea and Heart Failure Micha T. Maeder, MD Cardiology Division Kantonsspital St. Gallen Switzerland micha.maeder@kssg.ch Sleep Disordered Breathing (SDB) in HFrEF 700 HFrEF patients (LVEF
More informationHFpEF. April 26, 2018
HFpEF April 26, 2018 (J Am Coll Cardiol 2017;70:2476 86) HFpEF 50% or more (40-71%) of patients with CHF have preserved LV systolic function. HFpEF is an increasingly frequent hospital discharge. Outcomes
More informationObjectives. Systolic Heart Failure: Definitions. Heart Failure: Historical Perspective 2/7/2009
Objectives Diastolic Heart Failure and Indications for Echocardiography in the Asian Population Damon M. Kwan, MD UCSF Asian Heart & Vascular Symposium 02.07.09 Define diastolic heart failure and differentiate
More informationTitle. CitationHypertension Research, 33(3): Issue Date Doc URL. Type. Additional There Information.
Title Discharge use of angiotensin receptor blockers provi inhibitors on outcomes in patients hospitalized for Tsuchihashi-Makaya, Miyuki; Furumoto, Tomoo; Kinugaw Author(s) Daisuke; Yamada, Satoshi; Yokoshiki,
More informationHeart Failure Background, recognition, diagnosis and management
Heart Failure Background, recognition, diagnosis and management Speaker bureau: Novartis At the conclusion of this activity, participants will be able to: Recognize signs and symptoms of heart failure
More informationHeart Failure A Team Approach Background, recognition, diagnosis and management
Heart Failure A Team Approach Background, recognition, diagnosis and management Speaker bureau: Novartis At the conclusion of this activity, participants will be able to: Recognize signs and symptoms of
More informationEjection Fraction in Patients With Chronic Heart Failure. Diastolic Heart Failure or Heart Failure with Preserved Ejection Fraction
Diastolic Heart Failure or Heart Failure with Preserved Ejection Fraction Keith Miller MD Diastolic Heart Failure Risk Factors Common Risk Factors Aging Female gender Obesity Hypertension Diabetes mellitus
More informationNew CHF Patient in my Office: What Should I Do?
New CHF Patient in my Office: What Should I Do? Joseph Mishkin MD FACC Advanced Heart Failure, Transplantation and Mechanical Circulatory Support No disclosures Disclosures Clinical Presentation 38 year
More informationJournal of the American College of Cardiology Vol. 59, No. 11, by the American College of Cardiology Foundation ISSN /$36.
Journal of the American College of Cardiology Vol. 59, No. 11, 2012 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2011.11.040
More informationHeart Failure. Subjective SOB (shortness of breath) Peripheral edema. Orthopnea (2-3 pillows) PND (paroxysmal nocturnal dyspnea)
Pharmacology I. Definitions A. Heart Failure (HF) Heart Failure Ezra Levy, Pharm.D. HF Results when one or both ventricles are unable to pump sufficient blood to meet the body s needs There are 2 types
More informationCARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES
CARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES C. Liakos, 1 G. Vyssoulis, 1 E. Karpanou, 2 S-M. Kyvelou, 1 V. Tzamou, 1 A. Michaelides, 1 A. Triantafyllou, 1 P. Spanos, 1 C. Stefanadis
More information2016 ESC Heart Failure Guidelines: what is new? Piotr Ponikowski Wroclaw, Poland
2016 ESC Heart Failure Guidelines: what is new? Piotr Ponikowski Wroclaw, Poland Disclosures Consultancy fees and speaker s honoraria from: Amgen, Servier, Novartis, Johnson & Johnson, Merck, Berlin Chemie,
More informationΜαρία Μπόνου Διευθύντρια ΕΣΥ, ΓΝΑ Λαϊκό
Μαρία Μπόνου Διευθύντρια ΕΣΥ, ΓΝΑ Λαϊκό Diastolic HF DD: Diastolic Dysfunction DHF: Diastolic HF HFpEF: HF with preserved EF DD Pathophysiologic condition: impaired relaxation, LV compliance, LV filling
More informationWhat Have We Learned About Patients With Heart Failure and Preserved Ejection Fraction From DIG-PEF, CHARM-Preserved, and I-PRESERVE?
Journal of the American College of Cardiology Vol. 60, No. 23, 2012 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.04.064
More informationGALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS
GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS Table of Contents List of authors pag 2 Supplemental figure I pag 3 Supplemental figure II pag 4 Supplemental
More informationGerasimos Filippatos MD, FESC, FCCP, FACC
Gerasimos Filippatos MD, FESC, FCCP, FACC Head of HF Unit at Athens University Hospital, Greece President (2014-2016) of the HF Association of the European Society of Cardiology (ESC) Served as Chair of
More informationLCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor
The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction The Prospective comparison of ARNI with ARB on Management Of heart failure with preserved ejection
More informationIntroduction. Summary. Karim Gariani a, Alain Delabays b, Thomas V. Perneger c, Thomas Agoritsas a,c
Published 9 November 2011, doi:10.4414/smw.2011.13298 Cite this as: Use of brain natriuretic peptide to detect previously unknown left ventricular dysfunction in patients with acute exacerbation of chronic
More informationΟξεία Καρδιακή Ανεπάρκεια: Κλινική εικόνα, ταξινόμηση κινδύνου & προγνωστικοί δείκτες
Οξεία Καρδιακή Ανεπάρκεια: Κλινική εικόνα, ταξινόμηση κινδύνου & προγνωστικοί δείκτες Στράτος Θεοφιλογιαννάκος, MD, PhD Ιατρείο Καρδιακής Ανεπάρκειας, Γ Πανεπιστημιακή Καρδιολογική Κλινική ΑΠΘ, ΠΓΝ Ιπποκράτειο
More informationHeart Failure. Guillaume Jondeau Hôpital Bichat, Paris, France
Heart Failure Guillaume Jondeau Hôpital Bichat, Paris, France Epidemiology Importance of PEF Europe I-PREFER study. Abstract: 2835 Prevalence of HF Preserved LV systolic Function older (65 vs 62 y, p
More informationTopic Page: congestive heart failure
Topic Page: congestive heart failure Definition: congestive heart f ailure from Merriam-Webster's Collegiate(R) Dictionary (1930) : heart failure in which the heart is unable to maintain an adequate circulation
More informationThe Approach to Patients with Heart Failure and Mid-Range (40-50%) Ejection Fraction (HFmrEF)
The Approach to Patients with Heart Failure and Mid-Range (40-50%) Ejection Fraction (HFmrEF) 22 nd Annual Heart Failure 2018 an Update on Therapy April 21, 2018 Los Angeles, CA Barry Greenberg, M.D. Distinguished
More informationSGK 2016 Session: Postgraduate Course in Heart Failure Lausanne, 15. June 2016 Heart Failure Guidelines 2016
SGK 2016 Session: Postgraduate Course in Heart Failure Lausanne, 15. June 2016 Heart Failure Guidelines 2016 Matthias Nägele, MD University Hospital Zurich Disclosures I have nothing to disclose. The new
More informationNational Horizon Scanning Centre. Irbesartan (Aprovel) for heart failure with preserved systolic function. August 2008
Irbesartan (Aprovel) for heart failure with preserved systolic function August 2008 This technology summary is based on information available at the time of research and a limited literature search. It
More informationTHE PROPER APPROACH TO DIAGNOSING HEART FAILURE WITH PRESERVED EJECTION FRACTION
THE PROPER APPROACH TO DIAGNOSING HEART FAILURE WITH PRESERVED EJECTION FRACTION James C. Fang, MD, FACC Professor and Chief Cardiovascular Division University of Utah School of Medicine Disclosures Data
More informationEffects of heart rate reduction with ivabradine on left ventricular remodeling and function:
Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effects of heart rate reduction with ivabradine on left ventricular remodeling and function: results of the SHIFT echocardiography
More informationANGIOTENSIN RECEPTOR BLOCKERS ARE FIRST LINE TREATMENT : PRO
ANGIOTENSIN RECEPTOR BLOCKERS ARE FIRST LINE TREATMENT : PRO Prof Xavier Girerd M.D., Ph.D., F.E.S.C. Endocrinology Department Cardiovascular Prevention Unit Groupe Hospitalier Pitié-Salpêtrière Faculté
More informationHFpEF 2016 : Comorbidities and Outcomes
HFpEF 2016 : Comorbidities and Outcomes Christopher M. O Connor, MD, FACC CEO and Executive Director, Inova Heart and Vascular Institute Professor of Medicine, Duke University Editor in Chief, JACC: Heart
More informationST2 in Heart Failure. ST2 as a Cardiovascular Biomarker. Competitive Model of ST2/IL-33 Signaling. ST2 and IL-33: Cardioprotective
ST2 as a Cardiovascular Biomarker Lori B. Daniels, MD, MAS, FACC Professor of Medicine Director, Coronary Care Unit University of California, San Diego ST2 and IL-33: Cardioprotective ST2: member of the
More informationThe right heart: the Cinderella of heart failure
The right heart: the Cinderella of heart failure Piotr Ponikowski, MD, PhD, FESC Medical University, Centre for Heart Disease Clinical Military Hospital Wroclaw, Poland none Disclosure Look into the Heart
More informationCongestive Heart Failure: Outpatient Management
The Chattanooga Heart Institute Cardiovascular Symposium Congestive Heart Failure: Outpatient Management E. Philip Lehman MD, MPP Disclosure No financial disclosures. Objectives Evidence-based therapy
More informationHeart Failure with preserved ejection fraction (HFpEF)
Heart Failure with preserved ejection fraction (HFpEF) Dr. Pierpaolo Pellicori Hull York Medical School Kingston-upon-Hull United Kingdom Conflict of interest: none Heart failure is a contemporary problem
More informationAcute kidney injury and outcomes in acute decompensated heart failure in Korea
Acute kidney injury and outcomes in acute decompensated heart failure in Korea Mi-Seung Shin 1, Seong Woo Han 2, Dong-Ju Choi 3, Eun Seok Jeon 4, Jae-Joong Kim 5, Myeong-Chan Cho 6, Shung Chull Chae 7,
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More information*Christian M. Carlsen, 1 Mette Mouridsen, 1 Ahmad Sajadieh, 1 Lars Køber, 2 Olav W. Nielsen 1 ABSTRACT BACKGROUND
USE OF N-TERMINAL NATRIURETIC PEPTIDE IN A REAL- WORLD SETTING OF PATIENTS ADMITTED WITH ACUTE DYSPNOEA AND THE IMPLICATION FOR TRIAGING PATIENTS IN THE EMERGENCY DEPARTMENT *Christian M. Carlsen, 1 Mette
More informationThis is a cross-sectional analysis of the National Health and Nutrition Examination
SUPPLEMENTAL METHODS Study Design and Setting This is a cross-sectional analysis of the National Health and Nutrition Examination Survey (NHANES) data 2007-2008, 2009-2010, and 2011-2012. The NHANES is
More informationCopeptin in heart failure: Associations with clinical characteristics and prognosis
Copeptin in heart failure: Associations with clinical characteristics and prognosis D. Berliner, N. Deubner, W. Fenske, S. Brenner, G. Güder, B. Allolio, R. Jahns, G. Ertl, CE. Angermann, S. Störk for
More informationLeft Ventricular Diastolic Dysfunction in South Indian Essential Hypertensive Patient
Left Ventricular Diastolic Dysfunction in South Indian Essential Hypertensive Patient Dr. Peersab.M. Pinjar 1, Dr Praveenkumar Devarbahvi 1 and Dr Vasudeva Murthy.C.R 2, Dr.S.S.Bhat 1, Dr.Jayaraj S G 1
More informationThe Causes of Heart Failure
The Causes of Heart Failure Andy Birchall HFSN Right heart failure LVSD - HFREF Valve regurgitation or stenosis Dropsy CCF congestive cardiac failure Cor pulmonale Pulmonary hypertension HFPEF LVF Definitions
More informationWhich antihypertensives are more effective in reducing diastolic hypertension versus systolic hypertension? May 24, 2017
Which antihypertensives are more effective in reducing diastolic hypertension versus systolic hypertension? May 24, 2017 The most important reason for treating hypertension in primary care is to prevent
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response
More informationImpaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts Future Cardiovascular Events
Diabetes Care Publish Ahead of Print, published online May 28, 2008 Chronotropic response in patients with diabetes Impaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST ESC Congress 2011 Pathophysiology of HFPEF Vascular Remodeling & Pulmonary Hypertension Carolyn S.P. Lam MBBS, MRCP, MS Case Presentation 81 yo woman with dyspnoea &
More informationDoes quality of life predict morbidity or mortality in patients with atrial fibrillation (AF)?
Does quality of life predict morbidity or mortality in patients with atrial fibrillation (AF)? Erika Friedmann a, Eleanor Schron, b Sue A. Thomas a a University of Maryland School of Nursing; b NEI, National
More informationHFpEF: How to optimise management
HFpEF: How to optimise management Burkert Pieske M.D. Berlin, Germany Department of Internal Medicine and Cardiology, Campus Virchow Klinikum, Charité University Medicine Berlin, and Department of Internal
More informationDr.Kamal Waheeb AlGhalayini MD, SCC Med. MSc-Card Associate professor, Consultant Cardiology. Head non-invasive lab. Vice dean for clinical affaires
Dr.Kamal Waheeb AlGhalayini MD, SCC Med. MSc-Card Associate professor, Consultant Cardiology. Head non-invasive lab. Vice dean for clinical affaires King Abdulaziz University. Doc, I am fat because my
More informationDECLARATION OF CONFLICT OF INTEREST. None to declare
DECLARATION OF CONFLICT OF INTEREST None to declare Sympathetic nerve traffic, insulin resistance and baroreflex control of circulation in patients with resistant hypertension Gino Seravalle Marco Volpe
More informationHeart Failure. GP Update Refresher 18 th January 2018
GP Update Refresher 18 th January 2018 Heart Failure Dr. Alexander Lyon Senior Lecturer and Consultant Cardiologist Clinical Lead in Cardio-Oncology Royal Brompton Hospital, London UK President of British
More information